


# Exploring the sexual dimorphism of emotional disorders





## Yuhan Zhuo

Magdalena Koziol  
lab

Interested in a novel  
DNA modification in  
vertebrate genomes,  
called methylated  
deoxyadenosine



## Lijuan Tang

Li Zhang lab  
Exploring research  
interests





## Hongyun Wang

Ying Li lab  
Finding neural circuit  
mechanisms that  
mediate emotions  
and social behaviors



## Hao Wu

Peace Cheng lab  
Looking for possible  
targets for the  
treatment of  
mitochondrial  
diseases



- Background

## Sex differences in anxiety and depression clinical perspectives

Margaret Altemus<sup>a,b,\*</sup>, Nilofar Sarvaiya<sup>c</sup>, and C. Neill Epperson<sup>d,e,f</sup>

## Neurosteroid Biosynthesis Regulates Sexually Dimorphic Fear and Aggressive Behavior in Mice


Graziano Pinna · Roberto Carlos Agis-Balboa · Fabio Pibiri · Marianela Nelson ·  
Alessandro Guidotti · Erminio Costa

Hormonal Cycles, Brain Network  
Connectivity, and Windows of Vulnerability to  
Affective Disorder

Joseph M. Andreano,<sup>1,4,\*</sup> Alexandra Touroutoglou,<sup>2,4</sup> Brad Dickerson,<sup>2,4</sup> and Lisa Feldman Barrett<sup>1,3,4</sup>

Autism spectrum disorder, which is characterized by impaired social communication and restrictive, repetitive behaviors, is **severalfold** more prevalent in males than females (Rubenstein et al.,2015)


Women have **twice** the lifetime rates of depression and most anxiety disorders (Kessler et al., 1994, 1995; Weissman et al., 1994, 1996; Gater et al., 1998)



The screenshot shows a webpage from www.who.int. At the top, there is a navigation bar with a star icon, a lock icon, the URL 'www.who.int', and icons for a menu and refresh. Below the navigation bar is a header image showing two people sitting and talking. The main heading is 'Depression'. Below the heading, the date '30 January 2020' is displayed. There are five language selection buttons: 'العربية', '中文', 'Français', 'Русский', and 'Español'. Below the language buttons is a section titled 'Key facts' which contains three bullet points: 'Depression is a common mental disorder. Globally, more than 264 million people of all ages suffer from depression.', 'Depression is a leading cause of disability worldwide and is a major contributor to the overall global burden of disease.', and 'More women are affected by depression than men.'

Two recent meta-analyses found that when controlling for type of trauma, women do seem to be more likely than men to develop post-traumatic stress disorder (PTSD) in response to a number of stressors including combat (Crum-Cianflone & Jacoson, 2014), witnessing death and illness/injury (Freedman et al., 2002; Tolin and Foa, 2006)

But there is no significant difference in their learning and memory levels!




(Dulac & Kimchi , 2007)

Accept the same sensory stimulation, why do male and female have different behaviors?

What is the **source** of the difference in susceptibility to emotional disorders between the sexes?







BNST is an important region modulating anxiety

The human literature shows sex-specific changes in PTSD patients in **SNPs** of genes expressed in neurons in **BNST subpopulations**

This makes the BNST an excellent target for future research in PTSD and treatment for PTSD

(Lebow & Chen, 2016)

There is a group of neurons that highly express Suppression of tumorigenicity 18 protein (St18) in the posterior BNST





(Welch et al., 2019)


# Optogenetic activation of the neurons can trigger anxiety-like behavior in mice

(Rodriguez-Romaguera et al., 2020)


## OPTOGENETICS





It is worth noting that the BNST St18 neurons of male mice highly express *crhr2*, while female mice hardly express this gene




(Welch et al., 2019)






- Results

Devided into: CRHR1, CRHR2, calcitonin receptor, calcitonin receptor-like receeceptor, PTH1 receptor and SCT-R



It indiactes CRHR is a ancient protein, and CRHR separation is earliere than



# Fundamental information about CRHR2:

search uniprot with gene:crhr2 AND organism:"Homo sapiens (Human) [9606]"

**Protein** | Corticotropin-releasing factor receptor 2

**Gene** | CRHR2

**Organism** | *Homo sapiens (Human)*




**Status** |  Reviewed - Annotation score: ●●●●●● - Experimental evidence at protein level<sup>i</sup>

---

**Function<sup>i</sup>**




G-protein coupled receptor for CRH (corticotropin-releasing factor), UCN (urocortin), UCN2 and UCN3. Has high affinity for UCN. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and down-stream effectors, such as adenylate cyclase. Promotes the activation of adenylate cyclase, leading to increased intracellular cAMP levels.

**GO - Molecular function<sup>i</sup>**

- corticotrophin-releasing factor receptor activity 
- corticotrophin-releasing hormone receptor activity 
- G protein-coupled peptide receptor activity 
- peptide hormone binding 

[Complete GO annotation on QuickGO ...](#)

**GO - Biological process<sup>i</sup>**

- adenylate cyclase-modulating G protein-coupled receptor signaling pathway 
- cell surface receptor signaling pathway 
- G protein-coupled receptor signaling pathway 
- long-term synaptic potentiation 

[Complete GO annotation on QuickGO ...](#)

Functions:

**G-protein coupled receptor** for CRH (corticotropin-releasing factor), UCN (urocortin), UCN2 and UCN3.

## Region-specific roles of the corticotropin-releasing factor-urocortin system in stress

Marloes J A G Henckens<sup>1 2 3</sup>, Jan M Deussing<sup>2</sup>, Alon Chen<sup>1 2</sup>


Affiliations + expand

PMID: 27586075 DOI: 10.1038/nrn.2016.94


### Abstract

Dysregulation of the corticotropin-releasing factor (CRF)-urocortin (UCN) system has been implicated in stress-related psychopathologies such as depression and anxiety. It has been proposed that CRF-CRF receptor type 1 (CRFR1) signalling promotes the stress response and anxiety-like behaviour, whereas UCNs and CRFR2 activation mediate stress recovery and the restoration of homeostasis. Recent findings, however, provide clear evidence that this view is overly simplistic. Instead, a more complex picture has emerged that suggests that there are brain region- and cell type-specific effects of CRFR signalling that are influenced by the individual's prior experience and that shape molecular, cellular and ultimately behavioural responses to stressful challenges.


### Crfr2 mRNA expression



**Figure 2: Hypersensitivity of HPA axis to stress in mutant animals.**





**Figure 4: Increased anxiety-like behaviour of mutant animals as measured in the elevated plus maze and open-field test.**




CRHR2 activation is responsible for ensuring physiological and psychological homeostasis and counteracts the initial stress-response-provoking effects and anxiety-like behaviors

**What is the molecular basis for CRFR2 to function?**




CRHR2 belongs to a category of CRHR receptors, and its main ligands are CRH and UCN families. When CRHR are bound by natural ligands, they can activate downstream signal transduction pathways.




# Calcium signal is especially important


How CRHR2 affects the activities of St18 can be considered from two directions, but both require subsequent electrophysiological and pharmacological experiments to verify



(Luo, 2015)



(Cui et al., 2018)



# Agonists of CRHR2 & Three mutation sites related to drug-response in human

Agonists						
Key to terms and symbols		View all chemical structures			Click column headers to sort	
Ligand	Sp.	Action	Value	Parameter	Reference	
[ <sup>125</sup> I]urocortin 1 (mouse, rat)	Hs	Full agonist	10.0	pK <sub>d</sub>	28	
[ <sup>125</sup> I]sauvagine (frog)	Hs	Full agonist	9.6 – 9.8	pK <sub>d</sub>	8,12	
urocortin 1 (Sp: Human)	Hs	Full agonist	9.0 – 9.6	pK <sub>d</sub>	8,12	
urocortin 2 (Sp: Human)	Mm	Full agonist	9.3	pK <sub>d</sub>	21,29	
urocortin 2 (Sp: Mouse)	Mm	Full agonist	9.2	pK <sub>d</sub>	21	
urocortin 1 (Sp: Mouse, Rat)	Mm	Full agonist	8.7 – 9.4	pK <sub>d</sub>	12,14,21,28,36	▼
urocortin 1 (Sp: Mouse, Rat)	Hs	Full agonist	8.6 – 9.4	pK <sub>d</sub>	12	
urocortin 1 (Sp: Human)	Mm	Full agonist	8.8	pK <sub>d</sub>	14	
urocortin 2 (Sp: Human)	Rn	Full agonist	8.8	pK <sub>d</sub>	21	
urocortin 1 (Sp: Human)	Rn	Full agonist	8.7	pK <sub>d</sub>	14	
urocortin 2 (Sp: Mouse)	Rn	Full agonist	8.7	pK <sub>d</sub>	21	
urocortin 3 (Sp: Mouse, Rat)	Mm	Full agonist	8.7	pK <sub>d</sub>	21	
urocortin 2 (Sp: Human)	Hs	Full agonist	8.5 – 8.6	pK <sub>d</sub>	8	
sauvagine	Mm	Full agonist	8.4 – 8.7	pK <sub>d</sub>	14,28,36	
urotensin 1 (fish)	Mm	Full agonist	8.5	pK <sub>d</sub>	36	
sauvagine	Hs	Full agonist	7.6 – 9.3	pK <sub>d</sub>	8,12	
sauvagine	Rn	Full agonist	8.0 – 8.8	pK <sub>d</sub>	14,28	
urocortin 3 (Sp: Mouse, Rat)	Rn	Full agonist	8.3	pK <sub>d</sub>	21	

rs7793837 [*Homo sapiens*]

1.

Variant type: SNV  
 Alleles: A>C,T [Show Flanks]  
 Chromosome: 7:30687161 (GRCh38)  
 7:30726777 (GRCh37)  
 Canonical SPDI: NC\_000007.14:30687160:A:C,NC\_000007.14:30687160:A:T  
 Gene: CRHR2 (Varview)  
 Functional Consequence: genic\_upstream\_transcript\_variant,intron\_variant,5\_prime\_UTR\_variant  
 Clinical significance: drug-response  
 Validated: by frequency,by alfa,by cluster  
 MAF: T=0.271481/594 (ALFA)  
 T=0.166667/100 (NorthernSweden)  
 T=0.171943/315 (Korea1K)

...more

HGVS: NC\_000007.14:g.30687161A>C, NC\_000007.14:g.30687161A>T, NC\_000007.13:g.30726777A>C, NC\_000007.13:g.30726777A>T, NG\_029169.1:g.17943T>G, NG\_029169.1:g.17943T>A, XM\_017011752.2:c.-712T>G, XM\_017011752.2:c.-712T>A, XM\_024446865.1:c.-825T>C, XM\_024446865.1:c.-825T>A

[PubMed](#) [LitVar](#)

rs58713119 has merged into rs7793837 [*Homo sapiens*]

2.

Variant type: SNV  
 Alleles: A>C,T [Show Flanks]  
 Chromosome: 7:30687161 (GRCh38)  
 7:30726777 (GRCh37)  
 Canonical SPDI: NC\_000007.14:30687160:A:C,NC\_000007.14:30687160:A:T  
 Gene: CRHR2 (Varview)  
 Functional Consequence: genic\_upstream\_transcript\_variant,intron\_variant,5\_prime\_UTR\_variant  
 Clinical significance: drug-response  
 Validated: by frequency,by alfa,by cluster  
 MAF: T=0.271481/594 (ALFA)  
 T=0.166667/100 (NorthernSweden)  
 T=0.171943/315 (Korea1K)


...more

HGVS: NC\_000007.14:g.30687161A>C, NC\_000007.14:g.30687161A>T, NC\_000007.13:g.30726777A>C, NC\_000007.13:g.30726777A>T, NG\_029169.1:g.17943T>G, NG\_029169.1:g.17943T>A, XM\_017011752.2:c.-712T>G, XM\_017011752.2:c.-712T>A, XM\_024446865.1:c.-825T>C, XM\_024446865.1:c.-825T>A


rs10384543 has merged into rs7793837 [*Homo sapiens*]

3.

Variant type: SNV  
 Alleles: A>C,T [Show Flanks]  
 Chromosome: 7:30687161 (GRCh38)  
 7:30726777 (GRCh37)  
 Canonical SPDI: NC\_000007.14:30687160:A:C,NC\_000007.14:30687160:A:T



After CRFR2 is activated, the conformational changes are mainly concentrated in TM5, TM6, and TM7. TM6 unwinds at P321 6.47b-G324 6.50b and forms a 90° twist.



The interaction between the Helix 8 helix of the receptor and the N-terminus of Gβ is the main interface between the receptor and the Gs protein



All criticisms are accepted